METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT
First Claim
Patent Images
1. A method of treating hyperuricemia in a patient in need of treatment thereof, the method comprising the steps of:
- administering to a patient suffering from hyperuricemia and at least one second disease state, a therapeutically effective amount of at least one xanthine oxidoreductase inhibitor, wherein the subject is also receiving concomitant administration of theophylline to treat the at least one second disease state, andfurther wherein (i) the administration of the at least one xanthine oxidoreductase inhibitor to the patient does not result in theophylline toxicity to the patient; and
(ii) administration of the theophylline is in an amount ranging from about 90% to about 110% of a manufacturer'"'"'s recommended theophylline dosage amount in the absence of administration of at least one xanthine oxidoreductase inhibitor.
1 Assignment
0 Petitions
Accused Products
Abstract
The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer'"'"'s recommended dosage of theophylline.
9 Citations
27 Claims
-
1. A method of treating hyperuricemia in a patient in need of treatment thereof, the method comprising the steps of:
-
administering to a patient suffering from hyperuricemia and at least one second disease state, a therapeutically effective amount of at least one xanthine oxidoreductase inhibitor, wherein the subject is also receiving concomitant administration of theophylline to treat the at least one second disease state, and further wherein (i) the administration of the at least one xanthine oxidoreductase inhibitor to the patient does not result in theophylline toxicity to the patient; and
(ii) administration of the theophylline is in an amount ranging from about 90% to about 110% of a manufacturer'"'"'s recommended theophylline dosage amount in the absence of administration of at least one xanthine oxidoreductase inhibitor. - View Dependent Claims (2, 3, 4, 5)
-
-
6. A method of treating hyperuricemia in a patient in need of treatment thereof, the method comprising the steps of:
-
administering to a patient suffering from hyperuricemia and at least one second disease state, a therapeutically effective amount at least one xanthine oxidoreductase inhibitor, wherein said subject will also be receiving a concomitant administration of theophylline to treat the at least one second disease state, and further wherein (i) the administration of the at least one xanthine oxidoreductase inhibitor to said patient will not result in theophylline toxicity to said patient; and
(ii) administration of the theophylline will be in an amount ranging from about 90% to about 110% of a manufacturer'"'"'s recommended theophylline dosage amount in the absence of administration of at least one xanthine oxidoreductase inhibitor. - View Dependent Claims (7, 8, 9, 10, 11, 12, 13, 14)
-
-
15. A method of treating a patient suffering from at least one first disease state and in need of treatment thereof, the method comprising the step of:
-
administering to a patient suffering from at least one first disease state and at least one second disease state, a therapeutically effective amount of at least one xanthine oxidoreductase inhibitor, wherein the subject is also receiving concomitant administration of theophylline to treat the at least one second disease state, and further wherein (i) the administration of the at least one xanthine oxidoreductase inhibitor to the patient does not result in theophylline toxicity to the patient; and
(ii) administration of the theophylline is in an amount ranging from about 90% to about 110% of a manufacturer'"'"'s recommended theophylline dosage amount in the absence of administration of at least one xanthine oxidoreductase inhibitor. - View Dependent Claims (16, 17, 18, 19, 20)
-
-
21. A method of treating hyperuricemia in a patient suffering from gout and in need of treatment thereof, the method comprising the step of:
-
administering to a patient suffering from gout and hyperuricemia and at least one third disease state, a therapeutically effective amount of at least one xanthine oxidoreductase inhibitor, wherein the subject is also receiving concomitant administration of theophylline to treat the at least one third disease state, and further wherein (i) the administration of the at least one xanthine oxidoreductase inhibitor to the patient does not result in theophylline toxicity to the patient; and
(ii) administration of the theophylline is in an amount ranging from about 90% to about 110% of a manufacturer'"'"'s recommended theophylline dosage amount in the absence of administration of at least one xanthine oxidoreductase inhibitor. - View Dependent Claims (22, 23, 24, 25, 26, 27)
-
Specification